Trifluzic

What is Trifluzic?

It inhibits dopamine-induced effects through postsynaptic occlusion of dopamine receptors in the CNS. has it. It blocks alpha receptors and neutralizes the activity of histamine and serotonin.

Absorption:

Absorption of the drug depends on how it is taken. The drug is absorbed rapidly after intramuscular injection.

Release:

Widespread in the body, including milk. 91-99% is bound to protein. Its stable serum concentration is achieved in 4-7 days

Metabolism:

It is extensively metabolized in the liver but no active metabolites are formed.

Disposal:

Most of the drug is excreted in the urine through the kidneys. Some of the drug is excreted in the feces through the bile ducts.

Indications Trifluzic

  • Anxiety
  • Schizophrenia and other psychotic disorders

prohibited usage

Known hypersensitivity to photothiazines and related compounds, blood dyscrasias and decreased bone marrow function (hematologic side effects, coma disorders, CNS weakness brain damage, and adverse effects on blood pressure).

Caution

Heart disease, encephalitis, head injury, respiratory disease, epilepsy and other seizure disorders, glaucoma, hyperplasia, prostate, urinary retention, Parkinson’s and pheochromocytoma, hypocalcemia, impaired renal function, hepatic impairment or hepatitis Exposed to high heat.

Drug Interactions

Concomitant use of sympathomimetic drugs, including epinephrine, phenylephrine, and appetite suppressants, may reduce the vasoconstrictive and vasoconstrictive effects of this drug. Epinephrine as a vasoconstrictor in patients taking trifluoperazine May reverse the effect of epinephrine or further lower blood pressure.
Trifluoperazine may inhibit the blood pressure response to centrally administered antihypertensive drugs (such as clonidine, methyl dopa).
Beta-blocking drugs may increase the plasma concentration of trifluoperazine by inhibiting its metabolism and cause toxicity.
Concomitant use of propyl thiouracil increases the risk of agranulocytosis. Concomitant use of lithium may result in severe neurological intoxication or encephalitis-like syndrome and decreased therapeutic response to trifluoperazine.
Barbiturates and lithium can reduce the effect of phenonyazine.
Concomitant use with central nervous system depressants increases CNS attenuation.
Exposure to sunlight increases the risk of developing photosensitivity reactions.

side effects

Central Nerves: Extrapyramidal symptoms, lethargy (rarely), pseudoparkinsonism, drowsiness (often), neuroleptic malignant syndrome, dizziness, headache, insomnia, exacerbation of psychotic symptoms, fatigue, delayed dyskinesia

Cardiovascular: Slight standing blood pressure, tachycardia, changes (EKG)

Eye: Blurred vision, ocular changes (change in retinal pigmentation with prolonged use of the drug)

Gastrointestinal tract: dry mouth, constipation, nausea

Genitourinary: urinary retention, menstrual irregularities

Blood: transient leukopenia, agralonulocytosis

Liver: Obstructive jaundice

Metabolic: Weight gain

Skin: Allergic reactions, Intramuscular injection pain, Sensitivity to light, Skin rash, Sterile abscess

Other complications: Gynecomastia, cessation of milk secretion

Was this helpful?

0 / 0

Leave a Reply 0

Your email address will not be published. Required fields are marked *